On December 3, 2024, Fosun Pharma announced that its holding subsidiary Hebei Wanbang Fulin Pharmaceutical Co., Ltd.'s Chinese medicine class 3.1 new drug Taohong Siwu Granules has had its drug registration application accepted by the National Medical Products Administration. The new drug is mainly used to treat blood deficiency and blood stasis syndrome, with symptoms including irregular menstruation and blood stasis. By October 2024, Fosun Pharma had invested approximately 3.72 million yuan in the research and development of this new drug. This new drug's prescription is derived from the Qing Dynasty Chai Dehua's "Gynecological Bingjian" Taohong Siwu Decoction, and has been included in the ancient classic prescription catalog of the State Administration of Traditional Chinese Medicine. Although the drug registration application has...Show More

On December 3, 2024, Fosun Pharma announced that its holding subsidiary Hebei Wanbang Fulin Pharmaceutical Co., Ltd.'s Chinese medicine class 3.1 new drug Taohong Siwu Granules has had its drug registration application accepted by the National Medical Products Administration. The new drug is mainly used to treat blood deficiency and blood stasis syndrome, with symptoms including irregular menstruation and blood stasis. By October 2024, Fosun Pharma had invested approximately 3.72 million yuan in the research and development of this new drug. This new drug's prescription is derived from the Qing Dynasty Chai Dehua's "Gynecological Bingjian" Taohong Siwu Decoction, and has been included in the ancient classic prescription catalog of the State Administration of Traditional Chinese Medicine. Although the drug registration application has been accepted, it still needs to pass GMP compliance inspection and obtain drug registration approval before commercial production. Fosun Pharma stated that this acceptance will not have a significant impact on the group's current performance. Fosun Pharma reminds investors that due to the characteristics of the pharmaceutical industry, the sales performance of pharmaceutical products after listing may be affected by factors such as medication demand, market competition, and sales channels, and have significant uncertainty. Investors should pay attention to related risks.